John Glasspool

Insider Reports History

Reporting-owner location: Bannockburn, IL
Latest reporting-owner signature: /s/ John Glasspool
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for John Glasspool

Form 4 holding Director

RELMADA THERAPEUTICS, INC.

Security class: Stock Appreciation Rights
Shares / value: 164,000
Estimated value
Report date: 12 Dec 2025
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

RELMADA THERAPEUTICS, INC.

Security class: Stock Option (right to buy)
Shares / value: 100,000
Estimated value
Report date: 26 Jun 2025
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by John Glasspool

4 RLMD

RELMADA THERAPEUTICS, INC.

Report period: 12 Dec 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 16 Dec 2025, 09:29
Role: Director
Next action: Open filing details

4 RLMD

RELMADA THERAPEUTICS, INC.

Report period: 26 Jun 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 30 Jun 2025, 19:28
Role: Director
Next action: Open filing details

4 RLMD

RELMADA THERAPEUTICS, INC.

Report period: 24 May 2024
Transactions: 2
Transaction value: $0
Accepted by SEC: 29 May 2024, 21:24
Role: Director
Next action: Open filing details

4 RLMD

RELMADA THERAPEUTICS, INC.

Report period: 15 Dec 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 19 Dec 2023, 17:27
Role: Director
Next action: Open filing details

4 RLMD

RELMADA THERAPEUTICS, INC.

Report period: 25 May 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 30 May 2023, 17:08
Role: Director
Next action: Open filing details

4 RLMD

RELMADA THERAPEUTICS, INC.

Report period: 16 Dec 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 20 Dec 2022, 16:32
Role: Director
Next action: Open filing details

4 RLMD

RELMADA THERAPEUTICS, INC.

Report period: 17 Dec 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 26 May 2022, 18:41
Role: Director
Next action: Open filing details

4 RLMD

RELMADA THERAPEUTICS, INC.

Report period: 17 Dec 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 21 Dec 2021, 20:31
Role: Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .